Pathogenesis of respiratory syncytial virus

Current Opinion in Virology

Volumn 2, Issue 3, 2012, Pages 300-305

  Van Drunen Littel Van Den Hurk, Sylvia ^a,b   Watkiss, Ellen R ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HOST FACTOR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; GENETIC POLYMORPHISM; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW;

ANIMALS; HUMANS; IMMUNE EVASION; IMMUNOCOMPROMISED HOST; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL NONSTRUCTURAL PROTEINS; VIRULENCE FACTORS;

EID: 84862856767     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.01.008     Document Type: Review

References (55)

1. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D et al.: The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360:588-598.
2. Mailaparambil B, Grychtol R, Heinzmann A: Respiratory syncytial virus bronchiolitis and asthma - insights from recent studies and implications for therapy. Inflamm Allergy Drug Targets 2009, 8:202-207.
3. Gomaa MA, Galal O, Mahmoud MS: Risk of acute otitis media in relation to acute bronchiolitis in children. Int J Pediatr Otorhinolaryngol 2011, 76:49-51.
4. Centers for Disease Control and Prevention (CDC): Respiratory syncytial virus - United States, July 2007-June 2011. MMWR Morb Mortal Wkly Rep 2011, 60:1203-1206.
5. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N et al.: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
6. Collins PL, Melero JA: Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011, 162:80-99.
7. Lowther SA, Shay DK, Holman RC, Clarke MJ, Kaufman SF, Anderson LJ: Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children. Pediatr Infect Dis J 2000, 19:11-17. (Pubitemid 30046610)
8. Falsey AR, Walsh EE: Respiratory syncytial virus infection in elderly adults. Drugs Aging 2005, 22:577-587. (Pubitemid 41214551)
9. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
10. Committee on Infectious Diseases: From the American Academy of Pediatrics: Policy statements - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009, 124:1694-1701.
11. Karr CJ, Rudra CB, Miller KA, Gould TR, Larson T, Sathyanarayana S, Koenig JQ: Infant exposure to fine particulate matter and traffic and risk of hospitalization for RSV bronchiolitis in a region with lower ambient air pollution. Environ Res 2009, 109:321-327.
12. Bradley JP, Bacharier LB, Bonfiglio J, Schechtman KB, Strunk R, Storch G, Castro M: Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics 2005, 115:e7-e14. (Pubitemid 43046257)
13. Groskreutz DJ, Monick MM, Babor EC, Nyunoya T, Varga SM, Look DC, Hunninghake GW: Cigarette smoke alters respiratory syncytial virus-induced apoptosis and replication. Am J Respir Cell Mol Biol 2009, 41:189-198.
14. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS: The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007, 20:108-119. (Pubitemid 44967956)
15. Wright PF, Ikizler MR, Gonzales RA, Carroll KN, Johnson JE, Werkhaven JA: Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J Virol 2005, 79:8651-8654. (Pubitemid 40853565)
16. Wu W, Munday DC, Howell G, Platt G, Barr JN, Hiscox JA: Characterization of the interaction between human respiratory syncytial virus and the cell cycle in continuous cell culture and primary human airway epithelial cells. J Virol 2011, 85:10300-10309.
17. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E et al.: Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010, 182:1305-1314.
18. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP: Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 2011, 204:996-1002. A positive correlation between duration of clinical disease and RSV viral load was demonstrated. These observations challenge the immunopathology- based pathogenesis paradigm, and suggest that (early) treatment with antiviral agents might improve subsequent morbidity.
19. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE Jr, Goleniewska K et al.: A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 2009, 83:4185-4194.
20. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniewska K, Pretto C, Williams JV et al.: Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 2011, 85:5782-5793. Several clinical isolates were tested and shown to induce variable pathogenesis in BALB/c mice. A mouse model that shows characteristic RSV pathogenesis was developed with one of these isolates.
21. Bhoj VG, Sun Q, Bhoj EJ, Somers C, Chen X, Torres JP, Mejias A, Gomez AM, Jafri H, Ramilo O et al.: MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc Natl Acad Sci USA 2008, 105:14046-14051.
22. Hashimoto K, Ishibashi K, Ishioka K, Zhao D, Sato M, Ohara S, Abe Y, Kawasaki Y, Sato Y, Yokota S et al.: RSV replication is attenuated by counteracting expression of the suppressor of cytokine signaling (SOCS) molecules. Virology 2009, 391:162-170.
23. Ling Z, Tran KC, Teng MN: Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J Virol 2009, 83:3734-3742.
24. Bitko V, Shulyayeva O, Mazumder B, Musiyenko A, Ramaswamy M, Look DC, Barik S: Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-kappaB-dependent, interferon-independent mechanism and facilitate virus growth. J Virol 2007, 81:1786-1795. (Pubitemid 46214452)
25. Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, Murphy BR, Collins PL: The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 2008, 82:12191-12204.
26. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ: CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001, 2:732-738. (Pubitemid 32747163)
27. Polack FP, Irusta PM, Hoffman SJ, Schiatti MP, Melendi GA, Delgado MF, Laham FR, Thumar B, Hendry RM, Melero JA et al.: The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci USA 2005, 102:8996-9001. (Pubitemid 40881067)
28. Lukacs NW, Smit JJ, Schaller MA, Lindell DM: Regulation of immunity to respiratory syncytial virus by dendritic cells, tolllike receptors, and notch. Viral Immunol 2008, 21:115-122. (Pubitemid 351873371)
29. + T cells and Th17 cells, and to promote proliferation and activation of Th2 cells. Evidence for downregulation of maturation by NS1 and NS2 was provided.
30. Le Nouen C, Hillyer P, Winter CC, McCarty T, Rabin RL, Collins PL, Buchholz UJ: Low CCR7-mediated migration of human monocyte derived dendritic cells in response to human respiratory syncytial virus and human metapneumovirus. PLoS Pathogens 2011, 7:e1002105. RSV infection of human monocyte-derived dendritic cells (mo-DCs) led to reduced increase in CCR7 expression, and mo-DCs stimulated with RSV migrated inefficiently to CCL19. This suggests that impaired migration of RSV-stimulated DCs to lymphatic tissue contributes to impaired adaptive responses to RSV.
31. Beyer M, Bartz H, Horner K, Doths S, Koerner-Rettberg C, Schwarze J: Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection. J Allergy Clin Immunol 2004, 113:127-133. (Pubitemid 38096172)
32. Gill MA, Palucka AK, Barton T, Ghaffar F, Jafri H, Banchereau J, Ramilo O: Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis 2005, 191:1105-1115. (Pubitemid 40404369)
33. Rezaee F, Gibson LF, Piktel D, Othumpangat S, Piedimonte G: Respiratory syncytial virus infection in human bone marrow stromal cells. Am J Respir Cell Mol Biol 2011, 45:277-286. Human bone marrow stromal cells (BMSCs) were identified as a novel target for RSV, both in vivo and ex vivo. RSV infection of BMSCs resulted in structural and functional changes, which may influence the pathogenesis.
34. Groothuis JR, Hoopes JM, Jessie VG: Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther 2011, 28:91-109.
35. Belderbos ME, Houben ML, Wilbrink B, Lentjes E, Bloemen EM, Kimpen JL, Rovers M, Bont L: Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics 2011, 127:e1513-e1520. An analysis of cord blood vitamin D levels showed that vitamin D deficiency is correlated with increased risk of RSV LRTI in the first year of life This suggests vitamin D supplementation during pregnancy as a strategy to prevent RSV LRTI.
36. Miyairi I, DeVincenzo JP: Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev 2008, 21:686-703.
37. McNamara PS, Flanagan BF, Hart CA, Smyth RL: Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis 2005, 191:1225-1232.
38. Goetghebuer T, Isles K, Moore C, Thomson A, Kwiatkowski D, Hull J: Genetic predisposition to wheeze following respiratory syncytial virus bronchiolitis. Clin Exp Allergy 2004, 34:801-803. (Pubitemid 38736797)
39. McNamara PS, Ritson P, Selby A, Hart CA, Smyth RL: Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child 2003, 88:922-926. (Pubitemid 37194053)
40. Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB: Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med 1999, 159:1918-1924. (Pubitemid 29275064)
41. Phipps S, Lam CE, Mahalingam S, Newhouse M, Ramirez R, Rosenberg HF, Foster PS, Matthaei KI: Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood 2007, 110:1578-1586.
42. van Bleek GM, Osterhaus AD, de Swart RL: RSV 2010: recent advances in research on respiratory syncytial virus and other pneumoviruses. Vaccine 2011, 29:7285-7291.
43. van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs- Nolan J: Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 2007, 17:5-34.
44. Fulton RB, Meyerholz DK, Varga SM: Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol 2010, 185:2382-2392. A rapid accumulation of regulatory T-cells (Tregs) in the mediastinal lymph nodes and lungs of RSV infected mice was shown. In vivo depletion of Tregs before RSV infection led to delayed virus clearance and enhanced disease. This indicates that pulmonary Tregs play a critical role in limiting immunopathology during acute RSV infection.
45. Lee DC, Harker JA, Tregoning JS, Atabani SF, Johansson C, Schwarze J, Openshaw PJ: CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol 2010, 84:8790-8798. In increase in natural Treg numbers in the bronchoalveolar lavage fluid, lung, mediastinal lymph nodes, and spleen was demonstrated in RSVinfected mice. Depletion of Tregs led to increased weight loss. The Tregs were shown to play a critical role in regulating both innate and adaptive responses late during RSV infection.
46. Ruckwardt TJ, Bonaparte KL, Nason MC, Graham BS: Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol 2009, 83:3019-3028.
47. Mukherjee S, Lindell DM, Berlin AA, Morris SB, Shanley TP, Hershenson MB, Lukacs NW: IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol 2011, 179:248-258. Increased IL-6 and IL-17 levels were detected in tracheal aspirate samples from severely ill infants with RSV infection. A role for IL-17 in RSV pathogenesis was subsequently established in the mouse model.
48. Cormier SA, You D, Honnegowda S: The use of a neonatal mouse model to study respiratory syncytial virus infections. Expert Rev Anti-infective Ther 2010, 8:1371-1380.
49. Rosenberg HF, Domachowske JB: Pneumonia virus of mice: severe respiratory infection in a natural host. Immunol Lett 2008, 118:6-12.
50. Gershwin LJ: Bovine respiratory syncytial virus infection: immunopathogenic mechanisms. Anim Health Res Rev 2007, 8:207-213.
51. Antonis AF, de Jong MC, van der Poel WH, van der Most RG, Stockhofe-Zurwieden N, Kimman T, Schrijver RS: Agedependent differences in the pathogenesis of bovine respiratory syncytial virus infections related to the development of natural immunocompetence. J Gen Virol 2011, 91(Pt 10):2497-2506.
52. Sow FB, Gallup JM, Olivier A, Krishnan S, Patera AC, Suzich J, Ackermann MR: Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs. Am J Physiol Lung Cell Mol Physiol 2011, 300:L12-L24. A detailed characterization of the pathology induced by RSV A2 in newborn lambs demonstrated moderate clinical disease with increased virus titers, accumulation of macrophages, CD4+ and CD8+ T cells, and a transcriptional response of genes involved in inflammation, chemotaxis, and interferon response.
53. Scheerlinck JP, Snibson KJ, Bowles VM, Sutton P: Biomedical applications of sheep models: from asthma to vaccines. Trends Biotechnol 2008, 26:259-266.
54. Flecknoe SJ, Wallace MJ, Cock ML, Harding R, Hooper SB: Changes in alveolar epithelial cell proportions during fetal and postnatal development in sheep. Am J Physiol Lung Cell Mol Physiol 2003, 285:L664-L670. (Pubitemid 37022868)
55. Meyerholz DK, Grubor B, Fach SJ, Sacco RE, Lehmkuhl HD, Gallup JM, Ackermann MR: Reduced clearance of respiratory syncytial virus infection in a preterm lamb model. Microbes Infect 2004, 6:1312-1319. (Pubitemid 39539729)